A recent study revealed that RUNX1 and GATA3 were recurrent targets for mutation in ETP-ALL, and GATA3 and SH2B3 mutations were associated with poor prognosis in evaluating the relapse risk in T-ALL18. This evidence concerns the gene SH2B3 and acute lymphoblastic leukemia.